TSX gains on big banks strength
ImmunoPrecise Antibodies Ltd. reported its highest quarterly revenue to date in Q4 2025, reaching $7 million. The company’s gross margin also surged to 64%, up from 48% the previous year. Despite a significant improvement in adjusted EBITDA loss, the company’s stock saw a sharp decline, falling 14.74% to $1.72, with a further premarket drop of 9.9%. This market reaction occurred amid a backdrop of strategic advancements and operational efficiencies. According to InvestingPro data, the stock remains undervalued despite an impressive year-to-date return of over 390%.
Key Takeaways
- ImmunoPrecise achieved a record $7 million in Q4 revenue.
- Gross margin improved to 64% from 48% year-over-year.
- Stock price fell by 14.74% post-earnings announcement.
- Strategic collaborations and innovations in AI-driven drug development were highlighted.
- The company anticipates further growth in its BioStrand segment.
Company Performance
ImmunoPrecise’s performance in Q4 2025 marked a significant milestone, with the company achieving its highest quarterly revenue. The improvements in gross margin and a reduction in adjusted EBITDA loss underscore the company’s operational efficiencies and strategic focus. The BioStrand segment, in particular, showed robust growth, increasing by 180% year-over-year, driven by heightened interest in AI-driven preclinical drug development.
Financial Highlights
- Q4 Revenue: $7 million, the highest in company history.
- Full Year Revenue: $24.5 million.
- Q4 Gross Margin: 64%, up from 48% in the previous year.
- Full Year Gross Margin: 55%, up from 49%.
- Q4 Adjusted EBITDA Loss: $316,000, a significant improvement from a $1.7 million loss last year.
- Cash Position: $10.8 million as of April 30, 2025.
Market Reaction
Despite the positive financial results, ImmunoPrecise’s stock fell sharply by 14.74%, closing at $1.72. In premarket trading, the stock further declined by 9.9%. This reaction may reflect investor concerns over the broader market environment or specific company factors not detailed in the earnings call.
Outlook & Guidance
Looking ahead, ImmunoPrecise is completing the divestiture of its Dutch subsidiary and rebranding to emphasize its AI platform capabilities. The company expects continued growth in its BioStrand segment and anticipates revenue recognition from an oncology partnership in Q2.
Executive Commentary
CEO Jennifer Bass described fiscal year 2025 as a "standout year" for ImmunoPrecise. She emphasized the company’s positioning to deliver "earlier insights, stronger candidate selection, and faster decision making at scale." Interim CFO Joe Scheffler highlighted the company’s strong cash position and partner momentum as key strengths entering the new fiscal year.
Risks and Challenges
- Market Volatility: The recent stock decline suggests investor apprehension, which could affect future capital raising efforts.
- Competitive Pressure: As a bio-native AI platform, ImmunoPrecise faces competition from both traditional and emerging biotech firms.
- Regulatory Changes: The FDA’s move towards phasing out animal testing could necessitate rapid adaptation in drug development processes.
- Operational Costs: Despite cost reductions, maintaining competitive margins will require continued operational efficiencies.
- Strategic Execution: Successful execution of strategic collaborations and divestitures will be crucial for sustained growth.
Q&A
During the earnings call, analysts inquired about the development strategy for the GLP-one peptide and the payment structure of the oncology partnership. The company also addressed the impact of FDA guidance on AI drug development and confirmed the capacity for growth at its Canadian facility.
Full transcript - Immunoprecise Antibodies Ltd (IPA) Q4 2025:
Karen, Call Moderator/Operator, ImmunoPrecise Antibodies: Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibody’s Fourth Quarter and Fiscal Year End twenty twenty five Earnings Call. We appreciate your time and interest in IPA. Today’s call will be led by our CEO, Doctor. Jennifer Bass and Interim CFO, Joe Scheffler. They will provide a review of our financial performance, strategic initiatives and key operational highlights for the fourth quarter.
Please note that a copy of today’s presentation along with our financial statements will be available on our company website for your reference. We encourage you to review these materials to gain a deeper understanding of our performance and strategic direction. Once again, thank you, us, for joining. Before we proceed, I would like to remind everyone that today’s discussion will contain forward looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties.
Actual results could differ materially from those anticipated due to various factors, including, but not limited to, global political and economic factors, changes in market conditions and other unforeseen business risks. Please note that these forward looking statements are made as of today, and we undertake no obligation to update them as a result of new information or future events unless required by law. We strongly advise all participants to refer to our filings with the Securities and Exchange Commission, SEC, including our most recent Form 20 F and other periodic reports for a more detailed discussion of these risks and uncertainties and for a more complete understanding of the risks inherent in our business operations and the potential impact of our future performance. We appreciate your continued interest in immunoprecise antibodies. I will now turn the call over to IPA’s President and CEO, Doctor.
Jennifer Bass.
Jennifer Bass, President and CEO, ImmunoPrecise Antibodies: Thank you, Karen, and good morning, everyone. Thank you for joining us to discuss today’s, IPA’s fourth quarter and full year fiscal results for 2025. Fiscal year 2025 was a standout year for immuno precise antibodies capped with record setting fourth quarter. With $7,000,000 in revenue, our fourth quarter delivered the highest quarterly revenue in our company’s history. We also achieved gross margin of 64% in the fourth quarter, up from 48% in the ’4.
This improvement reflects the impact of our continued focus on operational efficiency and disciplined execution. For the full fiscal year ending 04/30/2025, we expanded our gross margins by 600 basis points from 49% to 55%. A key driver of this improvement was the exceptional growth of our BioStrand segment, which grew more than 180% year over year and delivered gross margins approaching 90%. As BioStrand continues this high growth path, we expect it to remain a strong contributor to the top line performance and to support continued margin expansion going forward. Another key highlight in the fourth quarter was our record adjusted EBITDA performance.
We narrowed the loss to just $316,000 a significant improvement compared to the loss of $1,700,000 in the same quarter last year. This marks meaningful progress and highlights the impact of our focus on operational efficiency and disciplined execution. In parallel and of note, our Canadian business showed strong growth in the fourth quarter. Sales orders reached $4,300,000 this quarter, more than double historical quarters. Year over year sales in Canada increased by 47% with quarterly orders coming in up 83%.
Orders from new clients rose 93% year over year and 80% quarter over quarter. As we noted on our last earnings call, we’ve been actively moving forward with the divestiture of our Dutch subsidiary. I’m pleased to share that we are now in the final stages of that process with due diligence progressing with a single focused buyer. While the time line has extended slightly beyond our original expectations, the transaction remains on track, and we anticipate near term completion. Once finalized, we expect this divestiture to sharpen our focus, streamline operations and generate additional cash to further strengthen our balance sheet and support our strategic priorities.
Shortly after the completion of the divestiture, we are rebranding to reinforce our position as a bio native AI platform that integrates AI, connected data, and advanced lab research. This signals our shift from a service oriented model to a customizable platform driven business aligned with an industry transformation where AI and data integration are reshaping how drug discovery is done. We are positioned to deliver earlier insights, stronger candidate selection, and faster decision making at scale. At the center is our Lens AI platform, powered by our patented HIF technology, which transforms fragmented biological information into a computable model for precision discovery and development. This approach strengthens our value to partners, drives growth, and enhance our competitive advantage across the full biologics continuum.
Now we will walk through some of our key milestones from the past several months. In February, we announced a strategic collaboration with Ribopro to combine their messenger RNA antigen expression technology with our AI and wet lab antibody discovery platform aimed at accelerating next generation therapeutic development offerings. In March, we strengthened our AI infrastructure through strategic collaboration with Vulture and deploying AMD’s MI 300x GPUs to support the growing demands of our discovery platform. This upgrade has significantly increased our processing speed, improved scalability, and reduced compute costs by up to 66%, all of which contribute to stronger operational efficiency and improved margin potential as we grow. Also in March, we entered into a strategic partnership with a publicly traded multibillion dollar technology company focused on antibody drug conjugates and bispecific antibodies in oncology.
This collaboration combines our B Cell Select platform and AI discovery capabilities with their research infrastructure. The agreement has an initial value of $8,000,000 with the potential to reach $10,000,000 over an eighteen to twenty four month term. In April, the FDA announced plans to phase out animal testing for monoclonal antibodies, a move that aligns with Lens AI’s in silico capabilities to predict toxicity, immune response, and efficacy, reducing reliance on animal models. Also in April, we launched our presence in Cambridge, Massachusetts, offering fee for service biologic services, extending our geographic reach and service footprint in a core US biotechnology hub. In May, we validated Lens AI’s ability to map antibody antigen interactions with accuracy comparable to X-ray crystallography, which is the industry gold standard, but in hours instead of weeks.
This breakthrough significantly accelerates early discovery and reduces the need for complex time consuming lab work. In June, we announced a major advance in our dengue vaccine program. Using our HFT powered LENS AI platform, we identified a highly conserved epitope shared across all four dengue serotypes, a key step toward a universal vaccine. We also released in silico data showing the structural stability of the target and its potential to trigger a safe balanced immune response, supporting its move toward translational studies. In the same month, we shared promising results from our AI designed GLP-one peptide, which matched or exceeded semaglutide and independent receptor activation assays.
This milestone shows the versatility of our platform beyond vaccines with clear applications across metabolic disease, infectious disease, and oncology. In July, we released a validation case study showing that Lens AI’s immunogenicity screening can predict antidrug antibody risks with strong correlation to real world results. In direct comparison, it outperformed a leading industry benchmark. This supports its value in helping drug developers identify and derisk problem candidates earlier in the discovery process. Also in July, we regained compliance with Nasdaq’s minimum bid price requirement following ten consecutive days of trading above the $1 threshold.
While procedural, this milestone reflects growing market confidence in the evolution of our platform driven bio native AI approach. On the leadership front, earlier this month, we welcomed John Lieber to our board. John brings over thirty years as a senior executive in biotechnology and life sciences with deep experience in capital markets, corporate strategy, and governance at NASDAQ listed companies, critical assets as we drive commercialization and scale platform adoption. We also expanded our advisory board with the appointment of Jeff Fried, an expert in health care data architecture and AI innovation. He’s played a pivotal role in integrating vector search capabilities into Lens AI’s platform via our intersystems partnership, further enabling large scale computation driven discovery workflows.
I’ll now turn things over to Mr. Joe Scheffler for our financial updates.
Joe Scheffler, Interim CFO, ImmunoPrecise Antibodies: Thank you, Jennifer. Please note that all numbers referenced are in Canadian dollars. As Jennifer mentioned earlier, BioStrand is currently delivering triple digit revenue growth with margin near 90%, underscoring the strong performance and long term value of this asset. Total revenue for the fourth quarter was $7,000,000 representing our highest quarterly revenues in the company’s history. Fourth quarter revenue increased 8.1% over the year ago quarter and 13.5% over the prior quarter.
The strong revenue growth was driven by increasing sales to our service platforms, in particular, our Revit B cell platform in Canada. Gross profit in the fourth quarter was 4,500,000.0 also at the highest level in the company’s history. This represented gross margin of 64%, up from 48% in the year ago quarter and 54% from the prior quarter. Gross margins in the fiscal year twenty twenty five were 55%, up from 49% in fiscal year twenty twenty four. The significant increase in our gross margins over the past year was due in part to increasing sales from our Biostrain division, which has margins approaching 90, much higher than our core wet lab business.
We expect our gross margins to trend higher over time as BioStrength continues its growth trajectory and represents a larger portion of our revenues. With our strong fourth quarter revenues, our fiscal year twenty twenty five revenues amounted to 24,500,000 a slight increase over our fiscal year twenty twenty four revenues. R and D expenses in Q4 were $1,100,000 down 14% from the fourth quarter of last year. Sales and marketing expenses were $1,000,000 in Q4, up from $900,000 in the year ago quarter. General and administrative expenses in the fourth quarter were 3,700,000.0 down 10% from the fourth quarter of last year.
In total, operating expenses, excluding amortization and onetime charges, declined to $5,800,000 down 7% from the year ago quarter and down 2% from the prior quarter. This year over year decline in operating expenses was driven primarily by lower G and A and lower R and D, while the sequential decline was driven by lower sales and marketing. Our decreasing operating expense is a result of our targeted focus on improving efficiencies within the company. Adjusted EBITDA for the fourth quarter was a loss of $316,000 a significant improvement from a loss of $1,700,000 in the year ago quarter and a loss of 1,700,000 in the prior quarter. As a percentage of revenues, adjusted EBITDA was a negative 5% in the fourth quarter, a big improvement over the negative 24% in the year ago quarter and a negative 25% in the prior quarter.
Again, these improvements are the result of reducing our expenses as well as improved gross margins. As of 04/30/2025, we held $10,800,000 in cash compared to $3,500,000 at 2024. With our strong cash position, validated AI economics and strong partner momentum, we believe we are entering a new fiscal year in a financially disciplined position to support our growth. Thank you. And now we’ll turn it back to the operator for the Q and A portion of our call.
Karen, Call Moderator/Operator, ImmunoPrecise Antibodies: We will now go to the question and answer session. We would like to ask if there are some questions from our okay. So our question comes from Swayampakula Ramakanth. Your line is open.
Swayampakula Ramakanth, Analyst: Thank you. Good morning, Jennifer and Fredrik. Couple of questions from me. Actually, congratulations on generating high efficiency, the GLP-one peptides that you were talking about in your in your opening remarks. So in terms of clinical development, what should we expect for them?
And also, you know, how do you plan to monetize this asset?
Jennifer Bass, President and CEO, ImmunoPrecise Antibodies: Hi, RK. This is Jennifer. Thanks for joining us, and thanks for your question. I appreciate that. So first of all, in terms of development, we have two partners that we’re working with at the moment.
One of them very specifically on the actual drug product manufacturing as well as formulation, and then an additional, partner who actually brings about novel ways to administer the drug product in a unique route of administration. And that partner is actually working with us not only on, on dosing escalation analysis and formulation, but also, has done the preclinical design and, validation in terms of, how we will execute on preclinical IND enabling data to support translational work and and, clinical design. We ourselves actually do not intend to take this product into the clinic. We do have an interested party who contacted us on the day of the very first press release with GLP that we are focused on demonstrating some of, these initial formulation study and dose dependent responses to where our hope and anticipation is that, we will be bringing along a financial sponsor that will then sponsor this in the clinical setting.
Swayampakula Ramakanth, Analyst: Okay. Perfect. Then, regarding the, the the biotech partner that you’re working with on the oncology assets. So for you to start recognizing, you know, some of those initial payments of the of the $8,000,000, what sort of milestones do you need to achieve? If you if you’re unable to spell out the milestones, at least what’s the kind of cadence that we should expect for that $8,000,000?
Can we see something in the fiscal year ’26? Or, you know, is it, like, one big lump payment that you will get at the end of whatever you are supposed to be doing Mhmm. In terms of the product?
Jennifer Bass, President and CEO, ImmunoPrecise Antibodies: That’s a good question. Yeah. That that’s a good question, RK, and I can appreciate that from your analyst perspective too. Looking to see, you know, when some of these financial components will start to hit the books. So it’s definitely not all in one lump sum, actually.
So we have just we are closing out on Thursday of this week, of course, our first quarter. We anticipate a significant amount of this program to actually be visible in our second quarter. So we’re launching quite a number of programs simultaneously for this particular partner that will then be moving through to a more advanced stage where we draw down and and recognize that revenue in q two. So that’s the time when I would expect you’ll start seeing the impact from that particular partner is, is this coming quarter. And then in terms of milestones, we really don’t have, like I mean, we have the usual milestones we have when we build a therapeutic for anyone, but we don’t have any, you know, milestones that are deal breakers here or anything unusual.
So we move through our process. As we go, we always are very transparent in sharing that data, with any given client to demonstrate the quality of the work and the product as it moves through the process. And, technically, every program we have has go no go aspects, but, we have approaching a 100% success rate on these platforms. So it’s pretty rare that something doesn’t continue to move through. So this program is is similar in the sense that we’re using highly validated platforms, and and we don’t have any particular set places where we have, a unique milestone that, could end up triggering, you know, the the halt, or or the completion of the program early.
Swayampakula Ramakanth, Analyst: Okay. And then, you’re you’re you know, we are all aware of the FDA’s guidance of trying to move, to AI based systems for preclinical drug development. Mhmm. So since that announcement had come out from the regulatory agency, have you know, what sort of traffic have you seen, you know, inbound, you know, for your services? And, you know, is there any way we can gauge as to, you know, how much the the Lens AI platform will start getting used, you know, in ’26, your fiscal year ’26.
Mhmm. Because because, you know, you you said in the PR that only 5% of your annual revenues at this point is coming from the, you know, the the the AI side of business. So I’m just trying to see how how quickly can that grow and what what magnitude could it grow to.
Karen, Call Moderator/Operator, ImmunoPrecise Antibodies: Mhmm.
Jennifer Bass, President and CEO, ImmunoPrecise Antibodies: Yeah. That’s a great question as well. So I think, you know, we’ve got a lot of eyes on the direction that, people with kind of earlier stage preclinical work are going in terms of, FDA guidance and applications. We have, you know, through some of our peer groups, recognized that there has been at least a couple of early stage purely in silico work that has supported, some unique cases already in their approval for clinical use from the FDA. But, overall, that’s probably a few years out before we get a firm transition in that space.
So we’ve been curious as well as to how this type of, work will transition to what we’re doing at at BioStrand. So we’ve definitely had an increase on inquiries in the particular areas that are very directly related to IND applications when it comes to clinical safety, patient safety, and uniqueness of patients being rolled in studies. But the area where we have seen really the most dramatic and material change, is kind of an interesting one because it’s, it corresponds as well to some of the more recent platforms that we’ve been fairly vocal about. So this includes our immunogenicity platform and then, which includes, of course, the analysis of these ADA responses and epitope mapping as well. And, it’s interesting because it’s difficult for us to know how much of that, even in communication with our clients, is due to the regulatory changes and people’s ability to very rapidly and less expensively and to very accurately, bolster the information that is going into their IND applications and dossiers.
Whereas previously, those were kind of rate limiting and time consuming steps. But interestingly enough, obviously, these do also provide significant, reassurances and support sometimes with aspects of, an IND application that people did not previously bother to do because of the time and the expense, where now they’re able to get more data and create a more a data rich dossier for the application to support IND work. So it does correspond as well with not only when we were able to go out and showcase these capabilities, but when we were able to take them publicly into the conference realm and share them with people in the industry. We saw a very, very rapid uptick, of people coming in to utilize, things like epitope mapping from BioStrand. So in response to, you know, to your question, the inbound traffic has been quite significant.
It’s not traffic coming in to replace IND applications, but instead to bolster them with data that they might not otherwise have had that might have been too cumbersome or time consuming for them to retrieve. And going forward for the second part of your question, we definitely expect that trend to continue. But there are other aspects of BioStrand that we also believe will continue to grow. So kind of across the board in these core capabilities, you know, this overall uptick that we’ve been seeing, we do expect that to continue into the next fiscal year only to be bolstered and supported by these newer applications that are gaining traction as well.
Swayampakula Ramakanth, Analyst: Thanks for that. One last question from me. Sure. Just just would like to understand if the divestment of the European facilities, you know, how far into it are you at this point? And also regarding your base business, you know, there were some transfers happening between Europe and and the Canadian facility.
Is that is that all done? And then is the is the Canadian facility, you know, able to, you know, have enough resources, you know, for for the for the work that you do?
Jennifer Bass, President and CEO, ImmunoPrecise Antibodies: Yeah. Great question. So how far along are we? We are extremely far along in the process. So I mentioned we do have one kind of dedicated buyer.
We’re really in the last stages of agreement in the sale and purchase agreement. So, so we’re extremely far along in this process and, really down to the the finer details of what needs to happen upon closing and post closing, for the full independence of both of these both of these locations for buyer and seller. With regard to Canada, so this is, this is actually quite interesting. You can see the rapid growth we’ve had in Canada over the last quarter or two. It really is faster growth than we’ve ever seen in any of our sites ever in the history of IPA.
They are able to take all the work that is coming in even though they are quite full. And and in part, they’re able to, we’re able to rely on Canada to continue to take this work because of the expansion, you know, that we’ve been that we’ve been doing in Canada. That expansion continues through fiscal year twenty six. And we had a very, very small number of programs that were really going between the location in Canada and in Europe. And so we we do not expect any sort of impact to Canada in a detrimental way there, but instead have found that we have been able to ensure that we can continue to take on all program all all programs holistically from beginning to end, whether it’s diagnostic or therapeutic in nature.
And, in addition to that, to also lean into the integration we’ve got done for the in silico work into the Canadian site. So I think we only mentioned on this briefly, previously, but about a year ago, we did begin the integration of LendAI applications into the Canadian site in a selected manner, which could really enhance and bolster the data packages coming out from Canada. And we completed the transfer of those applications, in in whole. So they’re actually being, you know, added to quotes and and are a a designated official part of all of our therapeutic programs. That actually happened last March.
So we’re also just beginning to see the impact of that, which serves, obviously, not only to enhance the programs that we’re offering, but to also ensure that every one of our clients is having the benefits of those in silico applications as well as the exposure to what those in silico applications can do for their work. So in short, base business will continue to go strong with Canada. Canada and BioStrand are in a really good position as we look at their pipelines moving forward, again, stronger than we have ever seen in this company in terms of the growth from quarter to quarter and year over year and the number of new clients blocking very specifically to that location. And and, you know, the divestiture, we were looking to see that quite quite rapidly here as we just go through the final details in the sale purchase agreement over, you know, the next week or so.
Swayampakula Ramakanth, Analyst: Perfect. Thank you very much, Jennifer, for taking all my questions.
Jennifer Bass, President and CEO, ImmunoPrecise Antibodies: Yes. Of course. Thank you, RK.
Karen, Call Moderator/Operator, ImmunoPrecise Antibodies: Thank you for your insightful questions. I will now hand the call over to doctor Jennifer Bass, our CEO, to conclude the call.
Jennifer Bass, President and CEO, ImmunoPrecise Antibodies: Thank you, Karen. To close, fiscal year 2025 definitely marked a clear turning point for IPA. We’ve delivered strong revenue. We’ve expanded gross margins by 600 basis points year over year, and we did significantly improve fourth quarter adjusted EBITDA, narrowing the Q4 loss by over 80% compared to the same period last year. These results reflect the tangible impact on our focused strategy, operational efficiencies and growing commercial traction across high value platforms.
Our BioStrand segment continues to grow rapidly, contributing strong margins and expanding pipeline opportunities. The nearing completion of our Dutch divestiture and planned rebrand will allow us to further concentrate resources where we see the greatest return potential. With a sharpened focused strengthened leadership and increasing momentum behind our platform driven model, we believe IPA is well positioned to drive long term value creation. We remain committed to building a scalable, capital efficient business that delivers innovation, margin leverage, and sustained shareholder growth. Thank you for your continued trust and your investment in IPA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.